Product Data Sheet



Farletuzumab

Cat. No.: HY-P99153 CAS No.: 896723-44-7 Molecular Weight: 145360 Target: Antibiotic Pathway: Anti-infection

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FR α) inhibitor. Farletuzumab is a humanized monoclonal antibody with high affinity for FR α . Farletuzumab possesses growth-inhibitory functions on cells overexpressing FR α . Farletuzumab can be used in research of cancer ^[1] .	
In Vitro	Farletuzumab (MORAb-003; 0-10 μ g/mL; CHO-FR cells) inhibits FR α -dependent cell growth and increases folate EC ₅₀ in a dose-dependent manner ^[1] . Farletuzumab (0.1-100 μ g/mL; IGROV-1 cells; 1 h) mediates tumor cytotoxicity via complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro ^[1] . Farletuzumab (0-10 μ g/mL; CHO-FR cells) inhibits phosphorylation of proteins by Lyn kinase, a member of the src family of kinases, thereby, blocking a FRa-mediated signaling pathway ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cytotoxicity Assay ^[1]	
	Cell Line:	IGROV-1 cells
	Concentration:	0.1, 1, 10, and 100 μg/mL
	Incubation Time:	1 hours
	Result:	Had significant cytotoxicity at IGROV-1 cells.

REFERENCES

[1]. Ebel W, et, al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun. 2007 Mar 9;7:6.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 1 of 1